The effect of a novel probiotic on metabolic biomarkers in adults with prediabetes and recently diagnosed type 2 diabetes mellitus: Study protocol for a randomized controlled trial

Trials

Volumn 18, Issue 1, 2017, Pages

  Palacios, Talia ^a   Vitetta, Luis ^b,c   Coulson, Samantha ^b   Madigan, Claire D ^a   Denyer, Gareth S ^a   Caterson, Ian D ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Medlab   (Australia)

Author keywords

Gut microbiota; Prediabetes; Probiotics; Type 2 diabetes mellitus

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; FATTY ACID; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MICROCRYSTALLINE CELLULOSE; PLACEBO; PROBIOTIC AGENT; TRIACYLGLYCEROL; AUTACOID; LIPID;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CLINICAL PROTOCOL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FECES ANALYSIS; FECES MICROFLORA; GLUCOSE BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN SENSITIVITY; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; LIFESTYLE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; METABOLIC DISORDER; METABOLOMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITION; RANDOMIZED CONTROLLED TRIAL; BLOOD; FECES; GASTROINTESTINAL TRACT; METABOLISM; METHODOLOGY; MICROBIOLOGY; NEW SOUTH WALES; PILOT STUDY; TIME FACTOR; TREATMENT OUTCOME;

BIOMARKERS; BLOOD GLUCOSE; CLINICAL PROTOCOLS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FECES; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HUMANS; INFLAMMATION MEDIATORS; LIPIDS; NEW SOUTH WALES; PILOT PROJECTS; PREDIABETIC STATE; PROBIOTICS; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME;

EID: 85008629238     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-016-1762-x     Document Type: Article

References (23)

1. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444:1027-31.
2. Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, Gibson GR, Delzenne NM. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia. 2007;50:2374-83.
3. Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, Griffin NW, Lombard V, Henrissat B, Bain JR, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science. 2013;341:1241214.
4. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, Wu Y, Li L, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19:576-85.
5. Vrieze A, Van Nood E, Holleman F, Salojarvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143:913-6. e917.
6. Cox LM, Blaser MJ. Pathways in microbe-induced obesity. Cell Metab. 2013;17:883-94.
7. Zeevi D, Korem T, Zmora N, Israeli D, Rothschild D, Weinberger A, Ben-Yacov O, Lador D, Avnit-Sagi T, Lotan-Pompan M, et al. Personalized nutrition by prediction of glycemic responses. Cell. 2015;163:1079-94.
8. World Health Organization and Food and Agriculture Organization of the United Nations. Probiotics in food: Health and nutritional properties and guidelines for evaluation. Rome: Fao food and nutrition; 2006.Available at http://www.fao.org/3/a-a0512e.pdf. [Accessed Jan 2016].
9. Muccioli GG, Naslain D, Backhed F, Reigstad CS, Lambert DM, Delzenne NM, Cani PD. The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol. 2010;6:392.
10. Sun J, Buys NJ. Glucose- and glycaemic factor-lowering effects of probiotics on diabetes: a meta-analysis of randomised placebo-controlled trials. Br J Nutr. 2016;115(7):1167-77.
11. Asemi Z, Khorrami-Rad A, Alizadeh SA, Shakeri H, Esmaillzadeh A. Effects of synbiotic food consumption on metabolic status of diabetic patients: a double-blind randomized cross-over controlled clinical trial. Clin Nutr. 2014;33(2):198-203.
12. Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-Jafarabadi M, Mofid V, Akbarian-Moghari A. Effect of probiotic yogurt containing Lactobacillus acidophilus and Bifidobacterium lactis on lipid profile in individuals with type 2 diabetes mellitus. J Dairy Sci. 2011;94:3288-94.
13. Bukowska H, Pieczul-Mroz J, Jastrzebska M, Chelstowski K, Naruszewicz M. Decrease in fibrinogen and LDL-cholesterol levels upon supplementation of diet with Lactobacillus plantarum in subjects with moderately elevated cholesterol. Atherosclerosis. 1998;137:437-8.
14. Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin JA, et al. SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. Ann Intern Med. 2013;158:200-7.
15. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011;34 Suppl 1:S62-9.
16. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462-70.
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-9.
18. National Health and Nutrition Examination Survey (NHaNES). Anthropometry Procedures Manual. Atlanta: Centers for Disease Control and Prevention; 2007.
19. Kiernan M, Schoffman DE, Lee K, Brown SD, Fair JM, Perri MG, Haskell WL. The Stanford Leisure-Time Activity Categorical Item (L-Cat): a single categorical item sensitive to physical activity changes in overweight/obese women. Int J Obes (Lond). 2013;37:1597-602.
20. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B Methodol. 1995;57:289-300.
21. Karlsson FH, Tremaroli V, Nookaew I, Bergstrom G, Behre CJ, Fagerberg B, Nielsen J, Backhed F. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013;498:99-103.
22. Napolitano A, Miller S, Nicholls AW, Baker D, Van Horn S, Thomas E, Rajpal D, Spivak A, Brown JR, Nunez DJ. Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PLoS One. 2014;9:e100778.
23. Greenway F, Wang S, Heiman M. A novel cobiotic containing a prebiotic and an antioxidant augments the glucose control and gastrointestinal tolerability of metformin: a case report. Benef Microbes. 2014;5:29-32.